Stanley Hazen, MD, PhD

Appointed
2002

Education & Fellowships

Fellowship - Barnes-Jewish Hospital
Endocrinology
St. Louis, MO USA
1996

Residency - Barnes-Jewish Hospital
Internal Medicine
St. Louis, MO USA
1994

Medical Education - Washington University School of Medicine
St. Louis, MO USA
1992

Undergraduate - Washington University
St. Louis, MO USA
1985

Additional Training

Professional Highlights

• Chair, Gordon Research Conference on Oxygen Radicals
• Jeffrey M Hoeg Arteriosclerosis, Thrombosis and Vascular Biology Award for Basic Science and Clinical Research
• Election, Association of American Physicians (AAP)
• Election, Fellow of American Heart Association Scientific Council for Arteriosclerosis
• Election, American Society for Clinical Investigation

Certifications

• Internal Medicine

Specialty Interests

Cardiovascular risk evaluation, coronary artery disease, high cholesterol, cardiovascular disease, cardiac rehabilitation, C-reactive protein testing, preventive cardiology

Awards & Honors

• Howard Hughes Medical Institute Research Fellowship for Physicians Award, 1995-1997 
• AAP, ASCI, and AFMR Certificate of Achievement Award, 1997 
• Marilyn Hansen American Thoracic Society Award, 1997
• Junior Faculty Award, American Federation of Medical Research, 1999 
• Gill Heart Institute Physician Scientist Award, University of Kentucky, Lexington Ky., 2001 
• Election, American Society for Clinical Investigation, 2003 
• John J. Ferchill Award for Innovation, Cleveland Clinic, 2004 
• Nomination, Howard Hughes Medical Institute Investigator Award, 2004 
• Vice-Chair, Gordon Research Conference on Oxygen Radicals, 2006 
•  Jeffrey M Hoeg Arteriosclerosis, Thrombosis and Vascular, 2007 

Innovations & Patents

• Patent Title: Diagnostic Methods for Asthma; U.S. Serial Number 09/253,380
• Patent Title: Myeloperoxidase, a Risk Indicator for Cardiovascular Disease; U.S., Serial Number 10/039,753
• Patent Title: Treating Inflammation and Associated Complications; Patent Reference Number 09531-030P01 (Pending)
• Patent Title: Methods of Identifying Subjects at Increased Risk for Cardiovascular Disease; U.S. Serial Number 60/259,340 (Pending)
• Patent Title: Monitoring Anti-inflammatory and Anti-oxidant Actions of Therapies; U.S. Serial Number (Pending)
• Patent Title: Diagnostic Method for Identifying Subjects at Risk for Atherosclerosis and its Complications; U.S. Serial Number (Pending)

Memberships

• American Society for Clinical Investigation
• American Association for the Advancement of Science
• American Heart Association Scientific Council for Arteriosclerosis
• American Society for Investigative Pathology
• American College of Cardiology

See publications for Stanley Hazen, MD, PhD.

(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 3/22/2023, Dr. Hazen has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting and/or Speaking. Dr. Hazen receives fees of $5,000 or more per year (or, in rare cases, equity or stock options) as a paid consultant, speaker or as a member of an advisory committee for the following companies:

• Zehna Therapeutics, LLC

Royalty Payments. Dr. Hazen receives or has the right to receive royalty payments for inventions or discoveries commercialized through the companies shown below:

• Cleveland HeartLab, Inc. (a wholly-owned subsidiary of Quest Diagnostics, Incorporated)
• Zehna Therapeutics, LLC

Right to Future Distribution of Cleveland Clinic Financial Interest. Dr. Hazen may receive future financial benefits from the Cleveland Clinic for inventions or discoveries commercialized through the companies shown below:

• Zehna Therapeutics, LLC

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.